Research programme: HLA-A2/MAGEA4 targetting TCR-T cell therapies - Regeneron Pharmaceuticals
Alternative Names: Research programme: HLA-A2/MAGE-A4 TCR-T cells - Regeneron PharmaceuticalsLatest Information Update: 30 Jun 2023
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer